* Cabaletta Bio Inc CABA.OQ reported a quarterly adjusted
loss
of 56 cents per share for the quarter ended in January, lower
than the same quarter last year, when the company reported EPS
of -37 cents. The mean expectation of ten analysts for the
quarter was for a loss of 55 cents per share. Wall Street
expected results to range from -73 cents to -44 cents per share.
* Reported revenue was zero; analysts expected zero.
* Cabaletta Bio Inc's reported EPS for the quarter was a
loss
of 56 cents.
* The company reported a quarterly loss of $27.6 million.
* Cabaletta Bio Inc shares had fallen by 18.3% this
quarter and
lost 73.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 15.8%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Cabaletta Bio Inc
is $30.00
This summary was machine generated from LSEG data August 8 at
04:37 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.55 -0.56 Missed
Mar. 31 2024 -0.48 -0.51 Missed
Dec. 31 2023 -0.39 -0.46 Missed
Sep. 30 2023 -0.40 -0.37 Beat